|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
American Journal of Roentgenology, Vol 160, 1171-1175, Copyright © 1993 by American Roentgen Ray Society
ARTICLES |
MJ Pentecost
Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia 19104.
After successful removal of a primary tumor, the exclusive or dominant site of metastatic spread is often the liver. Existing palliative treatments, particularly chemotherapy, have low success rates. Fortuitous physiologic circumstances allow the use of regional treatments, such as hepatic artery infusion therapy, for both primary and secondary malignant tumors in the liver. Despite encouraging results in early uncontrolled trials, subsequent randomized studies have failed to show survival benefit with regional infusion therapy via surgically implanted pumps in patients who have colorectal metastases, the most common tumor studied. Dissatisfaction with current treatments has led to a host of novel therapies, including embolization of liver tumors and the combined infusion of embolic particles and chemotherapeutic agents (i.e., chemoembolization).
This article has been cited by other articles:
![]() |
H. R. Alexander Jr., D. L. Bartlett, and S. K. Libutti Current Status of Isolated Hepatic Perfusion With or Without Tumor Necrosis Factor for the Treatment of Unresectable Cancers Confined to Liver Oncologist, October 1, 2000; 5(5): 416 - 424. [Abstract] [Full Text] |
||||
![]() |
L. M. Bavisotto, N. H. Patel, S. J. Althaus, D. M. Coldwell, H. V. Nghiem, T. Thompson, B. Storer, and C. R. Thomas Jr. Hepatic Transcatheter Arterial Chemoembolization Alternating with Systemic Protracted Continuous Infusion 5-Fluorouracil for Gastrointestinal Malignancies Metastatic to Liver: A Phase II Trial of the Puget Sound Oncology Consortium (PSOC 1104) Clin. Cancer Res., January 1, 1999; 5(1): 95 - 109. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |